Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is well positioned in the growing field of immune-driven medicine and has a strong financial outlook.

Bears say

Adaptive Biotechnologies is showing strong revenue growth and expanding margins, particularly in its Minimal Residual Disease segment driven by increasing penetration of its clonoSEQ test. However, the company's valuation is currently near 5-year highs and there are potential risks to the medical and life science tools sector that could impact the company's future performance. Additionally, while the company plans to separate its Immune Medicine business from its core MRD business by the end of 2026, there is no guarantee this will occur as planned.

Adaptive Biotechnologies (ADPT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 6 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.